<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730064</url>
  </required_header>
  <id_info>
    <org_study_id>7580</org_study_id>
    <nct_id>NCT03730064</nct_id>
  </id_info>
  <brief_title>Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression</brief_title>
  <official_title>Neuroinflammation as a Novel Target to Treat Bipolar Depression: A Pilot PET Study With [11C]PBR-28 and N-Acetyl Cysteine (NAC) Antidepressant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Lan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to understand what causes bipolar disorder and how medications treat bipolar
      depression. Particularly, we are looking at the importance of inflammation in the process. If
      you participate, you will have two different brain scans (MRI and PET scan). You will also
      have an experimental treatment for your depression named N-acetyl cysteine (NAC). The study
      is funded by the Columbia University Irving Institute to improve the treatment of bipolar
      disorder. Please contact us if you are interested in participating. Up to $600 in
      compensation if you are eligible and choose to participate. Up to 6 months of treatment for
      depression at no cost to you.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>Six weeks</time_frame>
    <description>Total score will be used; Ranges from 0 to 60 points; 60 is more most severe depression</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Bipolar depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine (NAC)</intervention_name>
    <description>Experimental medication with N-acetyl cysteine (NAC) for six weeks</description>
    <arm_group_label>Bipolar depressed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bipolar 2 disorder and meets criteria for a major depressive episode

          -  Age 18-60

          -  Females of child-bearing potential must be willing to use an acceptable method of
             birth control throughout the study

          -  Not currently taking psychotropic medications besides those allowed in the clinical
             trial

        Exclusion Criteria:

          -  Failed trial or intolerable side effects of NAC

          -  Diagnosis of other major psychiatric disorders such as lifetime schizophrenia,
             schizoaffective disorder, psychotic features of bipolar disorder, current drug or
             alcohol abuse or recent drug or alcohol dependence

          -  Significant active physical illness, including blood dyscrasias, lymphomas,
             hypersplenism, endocrinopathies, renal failure, chronic obstructive lung disease,
             autonomic neuropathies, peripheral vascular disease. Any disorders with inflammation,
             malignancy, autoimmune or infectious etiology. Systolic blood pressure &gt;140 or
             diastolic blood pressure &gt; 100 Hemoglobin &lt;11 in females or &lt;13 in males

          -  Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel
             in the body

          -  Current, past or anticipated exposure to radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin J Lan, MD PhD</last_name>
    <phone>646 774 7610</phone>
    <email>martin.lan@nyspi.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Lan, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Martin Lan</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>NAC</keyword>
  <keyword>N-acetyl cysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

